Back to Results
First PageMeta Content
Alcohols / Ethers / Phenols / Euphoriants / Buprenorphine / Opioid dependence / Methadone / Naloxone / Morphine / Chemistry / Organic chemistry / Morphinans


Agenda Paper 12 - National Clinical Guidelines for the use of Buprenorphine _and Suboxone_ - Attachment A.rtf
Add to Reading List

Document Date: 2011-01-16 23:40:43

Open Document

File Size: 245,06 KB

Share Result on Facebook

Company

Reckitt Benckiser / /

Country

United States / Australia / United Kingdom / /

Currency

pence / /

Event

Product Recall / Product Issues / /

Facility

Royal Australian College of General Practitioners / Royal Australasian College of Physicians / /

IndustryTerm

withdrawal services / liquid solution / buprenorphine products / chemical name / combination product / combination products / /

MedicalCondition

Withdrawal syndrome / opiate dependence / terminal and chronic pain / pregnant heroin user / pain / dependent heroin users / respiratory depression / /

MedicalTreatment

pharmacotherapies / /

Organization

National Expert Advisory Committee on Illicit Drugs / Therapeutic Goods Administration / National Drug and Alcohol Research Centre / Australasian Professional Society on Alcohol / Royal Australasian College of Physicians / Royal Australian College of General Practitioners / Department of Health / Turning Point Alcohol and Drug Centre / /

Person

Sue Henry-Edwards / Walter Ling / Leslie Amass / Chris Chapleo / Fergus Law / Eric C. Strain / David Newcombe / /

Position

General / Clinical Pharmacology General Information What / /

Product

medication regimes / Clinical Opiate / Scale / Objective Opioid / services / Subutex / naloxone hydrochloride / The optimal setting / heroin / naloxone / Suboxone / opioid / Getting / buprenorphine hydrochloride / syndrome / The role of buprenorphine / treatment / settings / Buprenorphine / /

Technology

68 6.2 Protocols / /

SocialTag